Voting results and Scrutinizers Report of the 40th Annual General Meeting held on 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals held its 40th AGM on 30th September 2025 via video conferencing, where all 8 resolutions were passed with overwhelming shareholder support (nearly 99.99% in favour on each). The total shares outstanding stood at 9,660,990, with 5,692,665 valid votes cast on most resolutions (about 58.9% participation). Key resolutions included adoption of audited standalone and consolidated financial statements for FY25, declaration of a dividend on equity shares, reappointment of Mr. Shashank Sandu as a director (retiring by rotation), ratification of cost auditor's remuneration, appointment of Swapnil J Dixit & Associates as secretarial auditor for five years, modification of a material related party transaction with Sandu Brothers Private Limited, and continuation of Shri Vijay Kajarekar as CFO beyond age 70. Promoter group holdings were excluded from voting on two resolutions where they were deemed interested. Book closure was from 23rd to 30th September 2025, with 10,395 shareholders on record and 46 attending the meeting.
All resolutions cleared with near-unanimous support, reflecting strong shareholder confidence in management and continuity of board leadership. The approval of the FY25 dividend and the related party transaction modification are the most material outcomes for retail investors, with no contentious opposition on any agenda item.